NCT00093223已完成2 期
A Phase II Safety Study of Systemic Nanoparticle Paclitaxel (ABI-007)for In-Stent Restenosis
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Celgene
- 入组人数
- 76
- 试验地点
- 1
- 主要终点
- Major Adverse Cardiac Events at 2 months following the stent procedure.
研究概览
简要总结
This trial will treat patients with a new chemotherapeutic medicine who have undergone a successful and uncomplicated de novo stent placement in up to two native coronary arteries. The purpose of the trial is to determine the appropriate dose of the new medicine for future trials and to evaluate the incidence of treatment-emergent adverse events and serious adverse events.
详细描述
See inclusion/exclusion criteria.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Undergone a successful and uncomplicated de novo stent placement in up to two native coronary arteries
- •Diagnosis of angina pectoris
- •At least 18 yrs old
- •If female, negative pregnancy test, non-lactating, and agree to utilize methods to prevent pregnancy
- •No previous treatment for In-Stent Restenosis
- •Patient agrees to comply with follow-up evaluation
- •Informed Consent obtained
- •Target vessel at least 3 mm diameter
- •Total stent less than 25 mm
- •Left ventricular ejection fraction at least 30%
- •No more than a single stent will be used per lesion
- •No more than one stented lesion per vessel with the exception that 2 lesions in a single vessel are allowable if covered by less than 25 mm of continuous stent
- •By Intravascular Ultrasound (IVUS), stent is fully opposed and has a minimum diameter of 3 mm or an in-stent luminal area of at least 7 mm2
- •TIMI 3 coronary flow post-stenting
- •No angiographic evidence of thrombus post-stenting
排除标准
- •More than two lesions treated with Percutaneous Coronary Intervention (PCI) or it is anticipated that additional lesions will require treatment within two months
- •Previous PCI within preceding three months
- •Previous participation in another study within 30 days
- •Life expectancy less than 12 months
- •Factors making follow-up difficult
- •Intended surgical intervention within 6 months of study participation
- •Investigator decision that patient is unsuitable
- •Recipient of heart transplant
- •Q wave or non-Q wave Myocardial Infarction (MI) with documented total CK greater than 2X normal upper limits within the preceding 24 hrs and the CK and CK-MB enzymes remain above normal at the time of the procedure
- •Cardiogenic shock
- •May refuse blood transfusion
- •Gastro-intestinal bleeding within past 3 months
- •Platelet count less than 100,000 cells/mm3
- •Impaired renal function
- •Known allergies/hypersensitivity to aspirin, clopidogrel bisulfate, and/or stainless steel
- •Exclusion Criteria Related to Angioplasty:
- •Intervention for another lesion occurred within 90 days or is planned for within 60 days after the index procedure
- •Stent is located in a coronary bypass
- •Unprotected left main disease with greater than 50% stenosis
- •Lost a side branch greater than 2 mm during stenting procedure
- •Angiographic evidence of thrombus post-stenting
- •Prior stent within 5 mm of target lesion
- •Left ventricular ejection fraction less than 30%
- •Greater than 50% stenosis proximal or distal to target lesion
- •Malposition, dissection, or unmasking of a significant narrowing in the inflow or outflow area of the implanted stent
- •Patient has received a drug coated stent as part of this procedure
- •Exclusion Criteria Related to ABI-007:
- •Absolute neutrophil count is less than 1500 cells/mm3
- •Platelet count is less than 100,000 cells/mm3
- •Bilirubin greater than 1.5 mg/dl or SGOT and SGPT greater than 2.5X upper limit of normal or alkaline phosphatase greater than 2.5X upper limit of normal
- •Creatinine greater than 2.5X upper limit normal
- •Pre-existing peripheral neuropathy of NCI toxicity Criteria Scale of Grade greater than 1
- •Immunosuppressed or has HIV or AIDS
- •Hypersensitivity to Taxane
研究组 & 干预措施
1
Experimental
35mg/m^2 infusion time is 3.5 minutes
干预措施: Paclitaxel Nanoparticle Albumin Bound (Drug)
2
Experimental
2 doses of 35mg.m^2 with the second dose given 2 months later
干预措施: Paclitaxel Nanoparticle Albumin Bound (Drug)
结局指标
主要结局
Major Adverse Cardiac Events at 2 months following the stent procedure.
时间窗: 2 months
Incidence of treatment-emergent adverse events and serious adverse events.
时间窗: 6 months
Safety and tolerability for ABI-007
时间窗: 2 Years
次要结局
- Evaluation of restenosis at 6 months.(6 months)
研究者
研究点 (1)
Loading locations...
相似试验
撤回
2 期
A Pilot Study to Evaluate the Efficacy and Safety of Neoadjuvant Chemoradiotherapy With Capecitabine, . . .Pancreatic CancerNCT01130701University of Massachusetts, Worcester
已完成
2 期
Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast CancerBreast CancerNCT00093145Celgene32
尚未招募
2 期
Neoadjuvant Immunochemotherapy for Adenocarcinoma of the Esophagogastric JunctionEsophageal CancerNCT06469060Shanghai Chest Hospital34
终止
2 期
A Study of Aplidin ( Plitidepsin) in Subjects With Advanced Prostate CancerProstate CancerNCT00780975PharmaMar8
招募中
2 期
SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.Non-small Cell Lung CancerNCT05351788Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.110